Gadolinium Study: Increased Risk for Death in Renal Patients with NSF

A new study published in the October issue of Arthritis & Rheumatism finds that in patients receiving hemodialysis, nephrogenic systemic fibrosis (NSF) is a predictor of early death. NSF is a potentially skin disease that triggers thickening of the skin, organs, and other tissues that makes it difficult to move and can lead to broken bones.

The study results indicate that exposure to gadolinium-based contrast dye significantly raises the risk of developing NSF in patients with kidney conditions.

The journal article noted that compared with patients who had not been exposured to gadolinium, those with exposure to the dye were almost 15 times more likely to develop "cutaneous changes of NSF."

Reseachers found that of patients receiving dialysis, 13 percent had NSF.

The Food and Drug Administration issued the strongest labeling for Gadolinium-based dyes, the so-called "black-box warning," on September 28, 2007.

If you have developed Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy following an MRI/MRA, you deserve the guidance of a lawyer experienced in such cases. Please complete the form below for a free legal evaluation.

Click To Talk To Us Online

Side Effects

Gadolinium Contrast Dye Side Effects Include NSF. Free Lawsuit Review
Side effects of gadolinium contrast dye: nephrogenic systemic fibrosis

FDA Warnings

FDA Requests Boxed Warning for Gadolinium Dye Used with MRIs
FDA Warning: "Black Box" to Be Placed on MRI Dyes with Gadolinium

Gadolinium Lawsuit

Gadolinium Lawsuit | MRI with Gadolinium Dye Immobilizes Woman
Wheelchair-Bound Woman Was Harmed by Gadolinium. Get Lawsuit Info

Name

Phone

strictly confidential

Your Question

Have you had an MRI or MRA with a contrast dye?
Do you have a prior history of kidney disease?
Were you diagnosed with Nephrongenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD)
Name
Email Address
Phone Number